MGMT and neoplasm: In the TTFields therapy arm, patients whose tumors were MGMT promoter methylation status positive had a numerically extended OS (95% CI) of 10 months (6.0–13.9) vs 6.5 months (4.5–7.4) in patients with tumor-negative status; HR (95% CI) was 0.77 (0.46–1.30), (P = 0.322, log-rank test; Fig. 3A).